image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 1.14
-5 %
$ 16 M
Market Cap
-1.5
P/E
1. INTRINSIC VALUE

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.[ Read More ]

The intrinsic value of one CPIX stock under the base case scenario is HIDDEN Compared to the current market price of 1.14 USD, Cumberland Pharmaceuticals Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CPIX

image
FINANCIALS
39.6 M REVENUE
-5.85%
-6.21 M OPERATING INCOME
-8.87%
-6.28 M NET INCOME
-11.14%
6.09 M OPERATING CASH FLOW
-27.91%
-106 K INVESTING CASH FLOW
99.23%
-7.42 M FINANCING CASH FLOW
-260.10%
9.09 M REVENUE
-7.75%
-1.25 M OPERATING INCOME
-1.09%
-1.51 M NET INCOME
-39.11%
476 K OPERATING CASH FLOW
155.57%
190 K INVESTING CASH FLOW
505.18%
-537 K FINANCING CASH FLOW
-73.41%
Balance Sheet Decomposition Cumberland Pharmaceuticals Inc.
image
Current Assets 35.7 M
Cash & Short-Term Investments 18.3 M
Receivables 9.76 M
Other Current Assets 7.63 M
Non-Current Assets 46.1 M
Long-Term Investments 0
PP&E 7.04 M
Other Non-Current Assets 39 M
Current Liabilities 28 M
Accounts Payable 14 M
Short-Term Debt 348 K
Other Current Liabilities 13.6 M
Non-Current Liabilities 24.5 M
Long-Term Debt 18.1 M
Other Non-Current Liabilities 6.45 M
EFFICIENCY
Earnings Waterfall Cumberland Pharmaceuticals Inc.
image
Revenue 39.6 M
Cost Of Revenue 6.07 M
Gross Profit 33.5 M
Operating Expenses 35 M
Operating Income -6.21 M
Other Expenses 68.5 K
Net Income -6.28 M
RATIOS
84.66% GROSS MARGIN
84.66%
-15.70% OPERATING MARGIN
-15.70%
-15.88% NET MARGIN
-15.88%
-21.21% ROE
-21.21%
-7.68% ROA
-7.68%
-14.76% ROIC
-14.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cumberland Pharmaceuticals Inc.
image
Net Income -6.28 M
Depreciation & Amortization 5.77 M
Capital Expenditures -453 K
Stock-Based Compensation 365 K
Change in Working Capital 4.63 M
Others -868 K
Free Cash Flow 5.64 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cumberland Pharmaceuticals Inc.
image
CPIX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Cumberland Pharmaceuticals Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
13.7 K USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Oct 31, 2024
Bought 37.2 USD
Young Caroline
Director
+ 31
1.2 USD
2 weeks ago
Oct 30, 2024
Bought 40.9 USD
Young Caroline
Director
+ 31
1.32 USD
2 weeks ago
Oct 29, 2024
Bought 38.4 USD
Young Caroline
Director
+ 31
1.24 USD
2 weeks ago
Oct 28, 2024
Bought 38.8 USD
Young Caroline
Director
+ 31
1.25 USD
3 weeks ago
Oct 25, 2024
Bought 38.1 USD
Young Caroline
Director
+ 31
1.23 USD
3 weeks ago
Oct 24, 2024
Bought 38.4 USD
Young Caroline
Director
+ 31
1.24 USD
3 weeks ago
Oct 23, 2024
Bought 39.1 USD
Young Caroline
Director
+ 31
1.26 USD
3 weeks ago
Oct 22, 2024
Bought 38.8 USD
Young Caroline
Director
+ 31
1.25 USD
3 weeks ago
Oct 21, 2024
Bought 38.8 USD
Young Caroline
Director
+ 31
1.25 USD
4 weeks ago
Oct 18, 2024
Bought 39.7 USD
Young Caroline
Director
+ 31
1.28 USD
1 month ago
Oct 17, 2024
Bought 40.3 USD
Young Caroline
Director
+ 31
1.3 USD
1 month ago
Oct 16, 2024
Bought 38.8 USD
Young Caroline
Director
+ 31
1.25 USD
1 month ago
Oct 15, 2024
Bought 40.3 USD
Young Caroline
Director
+ 31
1.3 USD
1 month ago
Oct 14, 2024
Bought 42.5 USD
Young Caroline
Director
+ 31
1.37 USD
1 month ago
Oct 11, 2024
Bought 43.1 USD
Young Caroline
Director
+ 31
1.39 USD
1 month ago
Oct 10, 2024
Bought 40.9 USD
Young Caroline
Director
+ 31
1.32 USD
1 month ago
Oct 09, 2024
Bought 40.6 USD
Young Caroline
Director
+ 31
1.31 USD
1 month ago
Oct 08, 2024
Bought 40.3 USD
Young Caroline
Director
+ 31
1.3 USD
1 month ago
Oct 07, 2024
Bought 40 USD
Young Caroline
Director
+ 31
1.29 USD
1 month ago
Oct 04, 2024
Bought 39.7 USD
Young Caroline
Director
+ 31
1.28 USD
1 month ago
Oct 03, 2024
Bought 39.7 USD
Young Caroline
Director
+ 31
1.28 USD
1 month ago
Oct 02, 2024
Bought 40 USD
Young Caroline
Director
+ 31
1.29 USD
1 month ago
Oct 01, 2024
Bought 39.4 USD
Young Caroline
Director
+ 31
1.27 USD
2 weeks ago
Oct 31, 2024
Bought 74.4 USD
Jones James
Director
+ 62
1.2 USD
2 weeks ago
Oct 30, 2024
Bought 81.8 USD
Jones James
Director
+ 62
1.32 USD
2 weeks ago
Oct 29, 2024
Bought 76.9 USD
Jones James
Director
+ 62
1.24 USD
2 weeks ago
Oct 28, 2024
Bought 77.5 USD
Jones James
Director
+ 62
1.25 USD
3 weeks ago
Oct 25, 2024
Bought 76.3 USD
Jones James
Director
+ 62
1.23 USD
3 weeks ago
Oct 24, 2024
Bought 76.9 USD
Jones James
Director
+ 62
1.24 USD
3 weeks ago
Oct 23, 2024
Bought 78.1 USD
Jones James
Director
+ 62
1.26 USD
3 weeks ago
Oct 22, 2024
Bought 77.5 USD
Jones James
Director
+ 62
1.25 USD
3 weeks ago
Oct 21, 2024
Bought 77.5 USD
Jones James
Director
+ 62
1.25 USD
4 weeks ago
Oct 18, 2024
Bought 79.4 USD
Jones James
Director
+ 62
1.28 USD
1 month ago
Oct 17, 2024
Bought 80.6 USD
Jones James
Director
+ 62
1.3 USD
1 month ago
Oct 16, 2024
Bought 77.5 USD
Jones James
Director
+ 62
1.25 USD
1 month ago
Oct 15, 2024
Bought 80.6 USD
Jones James
Director
+ 62
1.3 USD
1 month ago
Oct 14, 2024
Bought 84.9 USD
Jones James
Director
+ 62
1.37 USD
1 month ago
Oct 11, 2024
Bought 86.2 USD
Jones James
Director
+ 62
1.39 USD
1 month ago
Oct 10, 2024
Bought 81.8 USD
Jones James
Director
+ 62
1.32 USD
1 month ago
Oct 09, 2024
Bought 81.2 USD
Jones James
Director
+ 62
1.31 USD
1 month ago
Oct 08, 2024
Bought 80.6 USD
Jones James
Director
+ 62
1.3 USD
1 month ago
Oct 07, 2024
Bought 80 USD
Jones James
Director
+ 62
1.29 USD
1 month ago
Oct 04, 2024
Bought 79.4 USD
Jones James
Director
+ 62
1.28 USD
1 month ago
Oct 03, 2024
Bought 79.4 USD
Jones James
Director
+ 62
1.28 USD
1 month ago
Oct 02, 2024
Bought 80 USD
Jones James
Director
+ 62
1.29 USD
1 month ago
Oct 01, 2024
Bought 78.7 USD
Jones James
Director
+ 62
1.27 USD
2 weeks ago
Oct 31, 2024
Bought 74.4 USD
KAZIMI A J
Chairman and CEO
+ 62
1.2 USD
2 weeks ago
Oct 30, 2024
Bought 81.8 USD
KAZIMI A J
Chairman and CEO
+ 62
1.32 USD
2 weeks ago
Oct 29, 2024
Bought 76.9 USD
KAZIMI A J
Chairman and CEO
+ 62
1.24 USD
2 weeks ago
Oct 28, 2024
Bought 77.5 USD
KAZIMI A J
Chairman and CEO
+ 62
1.25 USD
3 weeks ago
Oct 25, 2024
Bought 76.3 USD
KAZIMI A J
Chairman and CEO
+ 62
1.23 USD
3 weeks ago
Oct 24, 2024
Bought 76.9 USD
KAZIMI A J
Chairman and CEO
+ 62
1.24 USD
3 weeks ago
Oct 23, 2024
Bought 78.1 USD
KAZIMI A J
Chairman and CEO
+ 62
1.26 USD
3 weeks ago
Oct 22, 2024
Bought 77.5 USD
KAZIMI A J
Chairman and CEO
+ 62
1.25 USD
3 weeks ago
Oct 21, 2024
Bought 77.5 USD
KAZIMI A J
Chairman and CEO
+ 62
1.25 USD
4 weeks ago
Oct 18, 2024
Bought 79.4 USD
KAZIMI A J
Chairman and CEO
+ 62
1.28 USD
1 month ago
Oct 17, 2024
Bought 80.6 USD
KAZIMI A J
Chairman and CEO
+ 62
1.3 USD
1 month ago
Oct 16, 2024
Bought 77.5 USD
KAZIMI A J
Chairman and CEO
+ 62
1.25 USD
1 month ago
Oct 15, 2024
Bought 80.6 USD
KAZIMI A J
Chairman and CEO
+ 62
1.3 USD
1 month ago
Oct 14, 2024
Bought 84.9 USD
KAZIMI A J
Chairman and CEO
+ 62
1.37 USD
1 month ago
Oct 11, 2024
Bought 86.2 USD
KAZIMI A J
Chairman and CEO
+ 62
1.39 USD
1 month ago
Oct 10, 2024
Bought 81.8 USD
KAZIMI A J
Chairman and CEO
+ 62
1.32 USD
1 month ago
Oct 09, 2024
Bought 81.2 USD
KAZIMI A J
Chairman and CEO
+ 62
1.31 USD
1 month ago
Oct 08, 2024
Bought 80.6 USD
KAZIMI A J
Chairman and CEO
+ 62
1.3 USD
1 month ago
Oct 07, 2024
Bought 80 USD
KAZIMI A J
Chairman and CEO
+ 62
1.29 USD
1 month ago
Oct 04, 2024
Bought 79.4 USD
KAZIMI A J
Chairman and CEO
+ 62
1.28 USD
1 month ago
Oct 03, 2024
Bought 79.4 USD
KAZIMI A J
Chairman and CEO
+ 62
1.28 USD
1 month ago
Oct 02, 2024
Bought 80 USD
KAZIMI A J
Chairman and CEO
+ 62
1.29 USD
1 month ago
Oct 01, 2024
Bought 78.7 USD
KAZIMI A J
Chairman and CEO
+ 62
1.27 USD
2 weeks ago
Oct 31, 2024
Bought 371 USD
Krogulski Kenneth
Director
+ 309
1.2 USD
2 weeks ago
Oct 30, 2024
Bought 408 USD
Krogulski Kenneth
Director
+ 309
1.32 USD
2 weeks ago
Oct 29, 2024
Bought 383 USD
Krogulski Kenneth
Director
+ 309
1.24 USD
2 weeks ago
Oct 28, 2024
Bought 386 USD
Krogulski Kenneth
Director
+ 309
1.25 USD
3 weeks ago
Oct 25, 2024
Bought 380 USD
Krogulski Kenneth
Director
+ 309
1.23 USD
3 weeks ago
Oct 24, 2024
Bought 383 USD
Krogulski Kenneth
Director
+ 309
1.24 USD
3 weeks ago
Oct 23, 2024
Bought 389 USD
Krogulski Kenneth
Director
+ 309
1.26 USD
3 weeks ago
Oct 22, 2024
Bought 386 USD
Krogulski Kenneth
Director
+ 309
1.25 USD
3 weeks ago
Oct 21, 2024
Bought 386 USD
Krogulski Kenneth
Director
+ 309
1.25 USD
4 weeks ago
Oct 18, 2024
Bought 396 USD
Krogulski Kenneth
Director
+ 309
1.28 USD
1 month ago
Oct 17, 2024
Bought 402 USD
Krogulski Kenneth
Director
+ 309
1.3 USD
1 month ago
Oct 16, 2024
Bought 386 USD
Krogulski Kenneth
Director
+ 309
1.25 USD
1 month ago
Oct 15, 2024
Bought 402 USD
Krogulski Kenneth
Director
+ 309
1.3 USD
1 month ago
Oct 14, 2024
Bought 423 USD
Krogulski Kenneth
Director
+ 309
1.37 USD
1 month ago
Oct 11, 2024
Bought 430 USD
Krogulski Kenneth
Director
+ 309
1.39 USD
1 month ago
Oct 10, 2024
Bought 408 USD
Krogulski Kenneth
Director
+ 309
1.32 USD
1 month ago
Oct 09, 2024
Bought 405 USD
Krogulski Kenneth
Director
+ 309
1.31 USD
1 month ago
Oct 08, 2024
Bought 402 USD
Krogulski Kenneth
Director
+ 309
1.3 USD
1 month ago
Oct 07, 2024
Bought 399 USD
Krogulski Kenneth
Director
+ 309
1.29 USD
1 month ago
Oct 04, 2024
Bought 396 USD
Krogulski Kenneth
Director
+ 309
1.28 USD
1 month ago
Oct 03, 2024
Bought 396 USD
Krogulski Kenneth
Director
+ 309
1.28 USD
1 month ago
Oct 02, 2024
Bought 399 USD
Krogulski Kenneth
Director
+ 309
1.29 USD
1 month ago
Oct 01, 2024
Bought 392 USD
Krogulski Kenneth
Director
+ 309
1.27 USD
7. News
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon. seekingalpha.com - 1 week ago
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update –        New Real World Study of 150,000 Patients Favors Caldolor over ketorolac   – –        DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations   – NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. prnewswire.com - 1 week ago
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). prnewswire.com - 1 week ago
New Study Compares Caldolor® (ibuprofen injection) to ketorolac –        Real World Study Compared Over 150,000 Adult & Pediatric Patients – –        Caldolor Associated with Fewer Adverse Drug Reactions – –        Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn. , Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (Nasdaq: CPIX) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. prnewswire.com - 1 week ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS NASHVILLE, Tenn. , Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. prnewswire.com - 2 weeks ago
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2024 Results Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon. seekingalpha.com - 3 months ago
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. prnewswire.com - 3 months ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS NASHVILLE, Tenn. , July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. prnewswire.com - 3 months ago
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript Start Time: 15:30 January 1, 0000 3:59 PM ET Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q1 2024 Earnings Conference Call May 07, 2024, 15:30 PM ET Company Participants A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Molly Aggas - Account Supervisor, Dalton Agency Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals First Quarter 2024 Financial Report and Company Update. seekingalpha.com - 6 months ago
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. prnewswire.com - 6 months ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024. prnewswire.com - 6 months ago
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants. prnewswire.com - 7 months ago
8. Profile Summary

Cumberland Pharmaceuticals Inc. CPIX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 16 M
Dividend Yield 0.00%
Description Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Contact 2525 West End Avenue, Nashville, TN, 37203 https://www.cumberlandpharma.com
IPO Date Aug. 11, 2009
Employees 91
Officers Mr. Adam S. Mostafa Managing Director Mr. A. J. Kazimi MBA Founder, Chairman, President & Chief Executive Officer Mr. James Lowrance Herman Executive Vice President of National Accounts & Chief Compliance Officer Mr. Chris T. Bitterman Vice President of Sales & Marketing Mr. Todd M. Anthony Vice President of Organizational Development Ms. Jean W. Marstiller Senior Vice President of Administrative Services & Corporate Secretary Ms. Erin Smith Gull Senior Corporate Relations Associate